Agenus (Agenus) LT-Debt-to-Total-Asset : 0.24 (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Agenus LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Agenus's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.24.

Agenus's long-term debt to total assets ratio increased from Mar. 2023 (0.18) to Mar. 2024 (0.24). It may suggest that Agenus is progressively becoming more dependent on debt to grow their business.

Agenus LT-Debt-to-Total-Asset Historical Data

The historical data trend for Agenus's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus LT-Debt-to-Total-Asset Chart

Agenus Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.14

0.25

0.12

0.18

0.24

Agenus Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.18	0.20	0.23	0.24	0.24

Agenus LT-Debt-to-Total-Asset Calculation

Agenus's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	75.279	/	313.913
	=	0.24

Agenus's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	61.756	/	256.559
	=	0.24

Agenus (NAS:AGEN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Agenus LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Agenus's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Agenus (Agenus) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (NAS:AGEN) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

AJ81:Germany AJ81:Germany

Address

3 Forbes Road, Lexington, MA, USA, 02421

Website

https://www.agenusbio.com

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Executives

Ulf Wiinberg	director
Steven J O'day	officer: Chief Medical Officer	2344 BANYAN DRIVE, LOS ANGELES CA 90049
Garo H Armen	officer: Chairman & CEO	3 FORBES ROAD, LEXINGTON MA 02421
Christine M Klaskin	officer: VP Finance	3 FORBES ROAD, LEXINGTON MA 02421
Adam Krauss	officer: Chief Legal Officer	139 GRANIT STREET, MEDFIELD MA 02052
Susan B Hirsch	director	280 OLD SOMERSET ROAD, WATCHUNG NJ 07069
Paul N Clark	director	5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Incyte Corp	10 percent owner	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Alex Duncan	officer: Chief Technology Officer	3 FORBES ROAC, LEXINGTON MA 02421
Christian Cortis	officer: See Remarks	3 FORBES ROAD, LEXINGTON MA 02421
Evan Kearns	officer: V.P. and General Counsel	AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
Jennifer Buell	officer: Chief Operating Officer	3 FORBES ROAD, LEXINGTON MA 02421
Allison M Jeynes-ellis	director	FLAT 52, WILLIAM HUNT MANSIONS, LONDON X0 SW13 8HT
Wadih Jordan	director	ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Brian Corvese	director	C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010